Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Inclusion Criteria: * Histologically proven diagnosis of recurrent and/or metastatic salivary duct cancer; adenocarcinoma, NOS; and AR expression in at least 70% of nuclei of neoplastic cells based on central review * Sufficient tissue must be available either historically or a biopsy must be done as a part of this study and sent to central review for patients enrolled in both cohorts * Presence of at least one uni-dimensional measurable lesion by CT-scan or MRI according to RECIST criteria version 1.1 (target lesion). * Patients older than 18 years old; * Performance Status ECOG 0-1; * Adequate bone marrow function: * WBC ≥ 3.5/10exp9L * absolute neutrophil count ≥ 1,5x10exp9/L * hemoglobin \> 9 g/dL * platelet count ≥ 100x10exp9/L * Adequate liver function: * AST \< 2.5 times upper limit of normal * ALT \< 2.5 times upper limit of normal * bilirubin \< 1.5 times upper limit of normal * the concomitant evidence of AST \< 2.5 times upper limit of normal, ALT \< 2.5 times upper limit of normal and bilirubin \> 1.5 times upper limit of normal is not allowed * Adequate renal function: * serum creatinine level (≤ 1.3 mg/dL) * calculated creatinine clearance ≥ 60 mL/min based on the standard Cockcroft and Gault formula * Adequate cardiac function as demonstrated by a clinically normal 12 lead ECG; additionally for patients who will receive Cisplatin and Doxorubicin adequate cardiac function should be demonstrated by a left ventricular ejection fraction (LVEF) ≥ 50% (within 2 week…